{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:47:52Z","timestamp":1787503672410,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kowa Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Background: Cholinesterase inhibitors (ChEIs) are commonly prescribed for the treatment of Alzheimer\u2019s disease (AD) and achieve long-term benefits for cognition and survival in real-world settings. However, the discontinuation rate is high due to their side effects, with gastrointestinal (GI) symptoms hampering long-term prescriptions. The risk of side effects associated with rivastigmine was previously shown to be lower with transdermal delivery than with oral capsules; however, this has yet to be examined in detail for donepezil, the most widely used ChEI. The daily application of a donepezil transdermal patch was officially approved in Japan in 2023. The incidence of side effects was lower with the donepezil transdermal patch than with oral donepezil in healthy volunteers, but has not yet been assessed in clinical settings. Results: We herein report three AD patients in two different memory clinics who developed GI symptoms with oral ChEIs that were attenuated by switching to the donepezil transdermal patch. Conclusions: The donepezil transdermal patch may improve tolerability and adherence in patients who develop gastrointestinal adverse effects with oral donepezil.<\/jats:p>","DOI":"10.3390\/brainsci16010098","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:02:07Z","timestamp":1768914127000},"page":"98","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Switching from Oral Cholinesterase Inhibitors to a Transdermal Donepezil Patch Attenuated Gastrointestinal Symptoms and Allowed Treatment Continuation in Three Patients with Alzheimer\u2019s Disease in Clinical Settings"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-4103","authenticated-orcid":false,"given":"Yumiko","family":"Motoi","sequence":"first","affiliation":[{"name":"The Medical Center for Dementia, Juntendo Hospital, Tokyo 113-0033, Japan"},{"name":"Department of Therapeutics for Dementia, Juntendo University, Tokyo 113-8421, Japan"},{"name":"Department of Neurology, Juntendo University, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1226-2425","authenticated-orcid":false,"given":"Nobuo","family":"Sanjo","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Institute of Science Tokyo, Tokyo 152-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"ref_1","unstructured":"(2025, December 31). World Alzheimer Report 2022. Available online: https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2022."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00401-022-02444-1","article-title":"Frequency of LATE neuropathologic change across the spectrum of Alzheimer\u2019s disease neuropathology: Combined data from 13 community-based or population-based autopsy cohorts","volume":"144","author":"Nelson","year":"2022","journal-title":"Acta Neuropathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-510X(02)00028-X","article-title":"Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital","volume":"196","author":"Akatsu","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40520-023-02675-6","article-title":"Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer\u2019s disease","volume":"36","author":"Zuliani","year":"2024","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3233\/JAD-190546","article-title":"Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis","volume":"71","author":"Matsunaga","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_8","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"2006","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer\u2019s disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3988\/jcn.2021.17.3.376","article-title":"Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer\u2019s Disease Patients in Asia","volume":"17","author":"Park","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2147\/PPA.S330372","article-title":"Effect of Psychoeducational Intervention on Donepezil Retention Rate and Analysis of Reasons for the Discontinuation in Patients with Alzheimer\u2019s Dementia: A Randomized Study","volume":"15","author":"Kamei","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0000000000000032","article-title":"Antidementia drug use among community-dwelling individuals with Alzheimer\u2019s disease in Finland: A nationwide register-based study","volume":"29","author":"Taipale","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1159\/000441894","article-title":"Donepezil Adherence, Persistence and Time to First Discontinuation in a Three-Year Follow-Up of Older People","volume":"5","author":"Ndukwe","year":"2015","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40266-017-0438-x","article-title":"Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching","volume":"34","author":"Fisher","year":"2017","journal-title":"Drugs Aging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14740338.2017.1351540","article-title":"Acetylcholinesterase inhibitors for treating dementia symptoms\u2014A safety evaluation","volume":"16","author":"Mohammad","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.2174\/0929867330666230112160522","article-title":"Side Effects of Alzheimer\u2019s Disease Treatment","volume":"30","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1533317510391240","article-title":"Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer\u2019s disease","volume":"26","author":"Grossberg","year":"2011","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ggi.14566","article-title":"Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer\u2019s disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study","volume":"23","author":"Nakamura","year":"2023","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_19","first-page":"13","article-title":"Saftey and Pharmacokinetics of Repeated Application of Donepezil Patch, a treatment for Alzheimer-type Dementia, in Healthy, Elderly Japanese Men","volume":"50","author":"Ikeda","year":"2022","journal-title":"Jpn. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/01.wnl.0000281846.40390.50","article-title":"Pharmacokinetic rationale for the rivastigmine patch","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","article-title":"IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease","volume":"69","author":"Winblad","year":"2007","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JAD-220530","article-title":"Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil","volume":"90","author":"Tariot","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"ref_23","unstructured":"(2025, December 31). CARE Case Report Guidelines. Available online: https:\/\/www.care-statement.org."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3988\/jcn.2011.7.3.137","article-title":"Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer\u2019s disease","volume":"7","author":"Han","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000501364","article-title":"Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer\u2019s Disease: A 24-Week, Open-Label, Multicenter Study in Japan","volume":"9","author":"Ueda","year":"2019","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10072-014-2002-3","article-title":"Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: A naturalistic prospective study in Alzheimer\u2019s disease","volume":"36","author":"Cagnin","year":"2015","journal-title":"Neurol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1533317509333037","article-title":"Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer\u2019s disease","volume":"24","author":"Sadowsky","year":"2009","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/WAD.0b013e318266fb02","article-title":"Patient adherence to transdermal rivastigmine after switching from oral donepezil: A retrospective claims database study","volume":"27","author":"Tian","year":"2013","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3988\/jcn.2022.18.4.428","article-title":"A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients with Alzheimer\u2019s Disease","volume":"18","author":"Han","year":"2022","journal-title":"J. Clin. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11357-021-00470-7","article-title":"Cholinesterase inhibitors for the treatment of dementia: Real-life data in Hungary","volume":"44","author":"Balazs","year":"2022","journal-title":"Geroscience"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Meguro, K., Kasai, M., Akanuma, K., Meguro, M., Ishii, H., and Yamaguchi, S. (2014). Donepezil and life expectancy in Alzheimer\u2019s disease: A retrospective analysis in the Tajiri Project. BMC Neurol., 14.","DOI":"10.1186\/1471-2377-14-83"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: A nationwide cohort study in subjects with Alzheimer\u2019s disease","volume":"34","author":"Nordstrom","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3233\/JAD-141089","article-title":"Cholinesterase inhibitors: Cardioprotection in Alzheimer\u2019s disease","volume":"42","author":"Monacelli","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/1\/98\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:22:49Z","timestamp":1768915369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/1\/98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["brainsci16010098"],"URL":"https:\/\/doi.org\/10.3390\/brainsci16010098","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]}}}